View Cart  

EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs

Drugmakers evaluating multiple sclerosis treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft European Medicines Agency (EMA) guideline.

To View This Article:


Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00